Summary: Methylphenidate may boost norepinephrine levels in the prefrontal cortex, which in turn regulates dopaminergic neurons firing in the striatum, when a reward is delivered. The study sheds new light on how medications for ADHD affect the reward system in the brain.
Source: OIST
Attention-deficit hyperactivity disorder (ADHD) is a neurobiological disorder characterized by symptoms of hyperactivity, inattention and impulsivity. People with the condition are often prescribed a stimulant drug called methylphenidate, which treats these symptoms. However, scientists do not fully understand how the drug works.
Now, researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) have identified how certain areas of the human brain respond to methylphenidate. The work may help researchers understand the precise mechanism of the drug and ultimately develop more targeted medicines for the condition.
Previous research suggests that people with ADHD have different brain responses when anticipating and receiving rewards, compared to individuals without ADHD. Scientists at OIST have proposed that in those with ADHD, neurons in the brain release less dopamine – a ‘feel-good’ neurotransmitter involved in reward-motivated behavior – when a reward is expected, with dopamine neurons firing more when a reward is given.
“In practice, what this means is that children, or even young adults, with ADHD may have difficulty engaging in behavior that doesn’t result in an immediate positive outcome. For example, children may struggle to focus on schoolwork, as it may not be rewarding at the time, even though it could ultimately lead to better grades. Instead, they get distracted by external stimuli that are novel and interesting, such as a classmate talking or traffic noises,” said Dr Emi Furukawa, first author of the study and a researcher in the OIST Human Developmental Neurobiology Unit, led by Professor Gail Tripp.
Scientists believe that methylphenidate helps people with ADHD maintain focus by influencing dopamine availability in the brain. Therefore, Dr Furukawa and her colleagues set out to examine how the drug affects a brain region called the ventral striatum, which is a vital component of the reward system and where dopamine is predominantly released.
“We wanted to take a look at how methylphenidate affects the ventral striatum’s responses to reward cues and delivery,” said Furukawa.
The study, which was recently published in the journal Neuropharmacology, was jointly conducted with scientists at D’Or Institute for Research and Education (IDOR) in Rio de Janeiro, Brazil. The collaboration allowed the researchers to combine expertise across multiple disciplines and provided access to IDOR’s functional magnetic resonance imaging (fMRI) facility.
Delving into the brain
The researchers used fMRI to measure brain activity in young adults with and without ADHD as they played a computer game that simulated a slot machine. The researchers scanned individuals in the ADHD group on two separate occasions – once when they took methylphenidate and another time when they took a placebo pill. Each time the reels of the slot machine spun, the computer also showed one of two cues, either the Japanese character ? (mi) or ? (so). While familiarizing themselves with the game before being scanned, the participants quickly learned that when the slot machine showed ?, they often won money, but when the slot machine showed ?, they didn’t. The symbol ? therefore acted as a reward-predicting cue, whereas ? acted as a non-reward-predicting cue.
The researchers found that when individuals with ADHD took the placebo, neuronal activity in the ventral striatum was similar in response to both the reward predicting and non-reward predicting cue. However, when they took methylphenidate, activity in the ventral striatum increased only in response to the reward cue, showing that they were now able to more easily discriminate between the two cues.
The researchers also explored how neuronal activity in the striatum correlated with neuronal activity in the medial prefrontal cortex – a brain region involved in decision-making that receives information from the outside world and communicates with many parts of the brain, including the striatum.
When the individuals with ADHD took placebo instead of methylphenidate, neuronal activity in the striatum correlated strongly with activity in the prefrontal cortex at the exact moment the reward was delivered, and the participants received money from the slot machine game. Therefore, the researchers believe that in people with ADHD, the striatum and the prefrontal cortex communicate more actively, which may underline their increased sensitivity to rewarding external stimuli. In participants who took methylphenidate, this correlation was low, as it was in people without ADHD.
The results implicate a second neurotransmitter, norepinephrine, in the therapeutic effects of methylphenidate. Norepinephrine is released by a subset of neurons common in the prefrontal cortex. Researchers speculate that methylphenidate might boost levels of norepinephrine in the prefrontal cortex, which in turn regulates dopamine firing in the striatum when rewards are delivered.
“It’s becoming clear to us that the mechanism by which methylphenidate modulates the reward response is very complex,” said Furukawa.
Tailoring New Therapies for ADHD
Despite the complexity, the scientists believe that further research could elucidate methylphenidate’s mechanism of action, which could benefit millions of people worldwide.
Pinning down how methylphenidate works may help scientists develop better therapies for ADHD, said Furukawa. “Methylphenidate is effective but has some side effects, so some people are hesitant to take the medication or give it to their children,” she explained. “If we can understand what part of the mechanism results in therapeutic effects, we could potentially develop drugs that are more targeted.”
Furukawa also hopes that understanding how methylphenidate impacts the brain could help with behavioral interventions. For example, by keeping in mind the difference in brain responses when children with ADHD anticipate and receive rewards, parents and teachers could instead help children with ADHD stay focused by praising them frequently and reducing the amount of distracting stimuli in the environment.
Source:
OIST
Media Contacts:
Tomomi Okubo – OIST
Image Source:
The image is credited to OIST.
Original Research: Open access
“Methylphenidate modifies reward cue responses in adults with ADHD: An fMRI study”. Emi Furukawa et al.
Neuropharmacology doi:10.1016/j.neuropharm.2019.107833.
Abstract
Methylphenidate modifies reward cue responses in adults with ADHD: An fMRI study
Attention deficit hyperactivity disorder (ADHD) has been associated with neural hyposensitivity to reward-predicting cues. Methylphenidate is widely used in the management of the disorder’s symptoms, but its effects on reward sensitivity in ADHD are unknown. The current study used fMRI to measure striatal responses to reward-predicting cues in adults with ADHD on and off methylphenidate and a control group, during a classical conditioning task. Responses to cued reward were also explored. Larger differences in the ventral striatum activation to reward cues versus non-reward cues were observed when the ADHD participants were on methylphenidate compared to placebo. In response to cued-reward outcome, an exploratory analysis showed methylphenidate reduced the BOLD time-series correlation between the dorsal striatum and dorsal medial prefrontal cortex. Methylphenidate’s therapeutic effects may be mediated by altering reward processing in individuals with ADHD.
